Market Cap : 16.38 B | Enterprise Value : 13.75 B | PE Ratio : 17.33 | PB Ratio : 3.99 |
---|
NAS:INCY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:INCY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Incyte's average Accounts Payable for the three months ended in Jun. 2022 was $174 Mil. Incyte's Cost of Goods Sold for the three months ended in Jun. 2022 was $51 Mil. Hence, Incyte's Days Payable for the three months ended in Jun. 2022 was 313.17.
The historical rank and industry rank for Incyte's Days Payable or its related term are showing as below:
During the past 13 years, Incyte's highest Days Payable was 33593.95. The lowest was 253.55. And the median was 332.00.
INCY's Days Payable is ranked better thanIncyte's Days Payable increased from Jun. 2021 (248.73) to Jun. 2022 (313.17). It may suggest that Incyte delayed paying its suppliers.
The historical data trend for Incyte's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Incyte's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Incyte's Days Payable distribution charts can be found below:
* The bar in red indicates where Incyte's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Incyte's Days Payable for the fiscal year that ended in Dec. 2021 is calculated as
Days Payable (A: Dec. 2021 ) | |||||||||
= | Average Accounts Payable | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Accounts Payable (A: Dec. 2020 ) | + | Accounts Payable (A: Dec. 2021 )) | / | count ) | / | Cost of Goods Sold (A: Dec. 2021 ) | * | Days in Period |
= | ( (98.767 | + | 172.11) | / | 2 ) | / | 151 | * | 365 |
= | 135.4385 | / | 151 | * | 365 | ||||
= | 327.38 |
Incyte's Days Payable for the quarter that ended in Jun. 2022 is calculated as:
Days Payable (Q: Jun. 2022 ) | |||||||||
= | Average Accounts Payable | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Accounts Payable (Q: Mar. 2022 ) | + | Accounts Payable (Q: Jun. 2022 )) | / | count ) | / | Cost of Goods Sold (Q: Jun. 2022 ) | * | Days in Period |
= | ( (152.547 | + | 194.77) | / | 2 ) | / | 50.6 | * | 365 / 4 |
= | 173.6585 | / | 50.6 | * | 365 / 4 | ||||
= | 313.17 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Incyte's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.
Tray Thomas | officer: Principal Accounting Officer | C/O INCYTE CORPORATION 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 |
Brawley Otis W | director | 5203 BRISTOL INDUSTRIAL WAY BUFORD GA 30518 |
High Katherine A | director | 3737 MARKET STREET SUITE 1300 PHILADELPHIA PA 19104 |
Harrigan Edmund | director | |
Morrissey Michael James | officer: EVP, Head of Tech. Operations | IN CARE OF INCYTE CORPORATION 1801 AUGUSTINE CUT OFF WILMINGTON DE 19803 |
Dickinson Jonathan Elliott | officer: EVP, General Manager, Europe | CARE OF INCYTE CORPORATION 1801 AUGUSTINE CUT OFF WILMINGTON DE 19803 |
Stamoulis Christiana | officer: EVP & Chief Financial Officer | C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY ST CAMBRIDGE MA 02139 |
Dhanak Dashyant | officer: EVP & Chief Scientific Officer | C/O INCYTE CORPORATION 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 |
Pasquale Maria E | officer: EVP & General Counsel | C/O INCYTE CORPORATION 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 |
Fouse Jacqualyn A | director | C/O DICK'S SPORTING GOODS 345 COURT STREET CORAOPOLIS PA 15108 |
Iyengar Vijay K | officer: EVP GPS, BD, & Licensing | 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 |
Stein Steven H | officer: EVP & Chief Medical Officer | 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 |
Trower Paul | officer: VP, Finance & Prin Acc Officer | 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 |
Clancy Paul J | director | C/O BIOGEN IDEC INC. 14 CAMBRIDGE CENTER CAMBRIDGE MA 02142 |
Bienaime Jean Jacques | director | 925 PAGE MILL ROAD PALO ALTO CA 94304 |
From GuruFocus
Other Sources
By tipranks.com 2022-02-09
By tipranks.com 2022-02-11
By Zacks 2022-01-31
By Seekingalpha 2022-01-24
By Zacks 2022-01-17
By Zacks 2022-03-18
By Zacks 2022-02-09
By Zacks 2021-12-16
By Zacks 2022-01-27
By Zacks 2022-02-03
By tipranks.com 2022-02-10
By tipranks.com 2022-02-08
By tipranks.com 2022-03-14
By Zacks 2022-02-03
By Zacks 2022-03-10